• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2018/12/10
SHIONOGI and Ube Industries Entered into Strategic Research Collaboration for Novel Anti-RS Virus Drug Candidates
2018/12/06
SHIONOGI Invests in Vast Therapeutics for Future In-license of Nitric Oxide Inhaled Antimicrobial Drug Candidate
2018/11/09
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2018/11/08
SHIONOGI TO PRESENT CLINICAL DATA ON MULPLETA®(lusutrombopag) AT THE LIVER MEETING ®2018 OF THE AMERICAN ASSOCIATIONFOR THE STUDY OF LIVER DISEASES (AASLD)
2018/11/06
Audio webcasting: First Half of FY2018 Financial Results
2018/10/29
Financial Results for the Second Quarter of FY2018
2018/10/29
Notice Regarding Reorganization of Manufacturing Subsidiaries through Company Split and Merger
2018/10/25
Pivotal Trial Results for Shionogi’s Cefiderocol Published in The Lancet Infectious Diseases
2018/10/25
Shionogi Announces FDA Approval of XOFLUZA™ (Baloxavir Marboxil) - for the Treatment of Acute, Uncomplicated Influenza -
2018/10/18
Shionogi to Announce Corporate Personnel Reassignment
2018/10/17
Shionogi Establishes New Manufacturing Subsidiary in Japan
2018/10/12
Shionogi Received “2018 Award for Excellence in Corporate Disclosure” From the Securities Analysts Association of Japan (SAAJ)
2018/10/10
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)